Immunodiagnostic Systems Holdings PLC is a medical devices business based in the UK. Immunodiagnostic Systems Holdings shares (IDH.LSE) are listed on the London Stock Exchange (LSE) and all prices are listed in pence sterling. Its last market close was 211.3p – a decrease of 6.09% over the previous week. Immunodiagnostic Systems Holdings employs 276 staff and has a trailing 12-month revenue of around £34.3 million.
Since the stock market crash in March caused by coronavirus, Immunodiagnostic Systems Holdings's share price has had significant negative movement.
Its last market close was 211.3p, which is 4.39% down on its pre-crash value of 221p and 32.06% up on the lowest point reached during the March crash when the shares fell as low as 160p.
If you had bought £1,000 worth of Immunodiagnostic Systems Holdings shares at the start of February 2020, those shares would have been worth £829.26 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £1,030.72.
|Latest market close||211.3p|
|52-week range||158.7064p - 307.4936p|
|50-day moving average||211.2857p|
|200-day moving average||231.3357p|
|Wall St. target price||268.59p|
|Dividend yield||0.02p (0.9%)|
|Earnings per share (TTM)||1.3p|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2021-01-08)||-1.87%|
|1 month (2020-12-18)||-2.33%|
|3 months (2020-10-16)||-12.50%|
|6 months (2020-07-17)||-10.64%|
|1 year (2020-01-17)||-19.23%|
|2 years (2019-01-17)||12.00%|
|3 years (2018-01-17)||-27.59%|
|5 years (2016-01-15)||-7.39%|
Valuing Immunodiagnostic Systems Holdings stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Immunodiagnostic Systems Holdings's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Immunodiagnostic Systems Holdings's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 162x. In other words, Immunodiagnostic Systems Holdings shares trade at around 162x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Immunodiagnostic Systems Holdings's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £3.2 million.
The EBITDA is a measure of a Immunodiagnostic Systems Holdings's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||£34.3 million|
|Gross profit TTM||£17.4 million|
|Return on assets TTM||-2.11%|
|Return on equity TTM||0.69%|
|Market capitalisation||£60.4 million|
TTM: trailing 12 months
Dividend payout ratio: 9500% of net profits
Recently Immunodiagnostic Systems Holdings has paid out, on average, around 9500% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.9% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Immunodiagnostic Systems Holdings shareholders could enjoy a 0.9% return on their shares, in the form of dividend payments. In Immunodiagnostic Systems Holdings's case, that would currently equate to about 0.02p per share.
Immunodiagnostic Systems Holdings's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 16 July 2020 (the "ex-dividend date").
Over the last 12 months, Immunodiagnostic Systems Holdings's shares have ranged in value from as little as 158.7064p up to 307.4936p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Immunodiagnostic Systems Holdings's is 0.8. This would suggest that Immunodiagnostic Systems Holdings's shares are less volatile than average (for this exchange).
Immunodiagnostic Systems Holdings PLC develops, manufactures, and sells in-vitro diagnostic tests to the clinical laboratory market in the United Kingdom, the United States, Germany, France, and internationally. It develops, manufactures, and markets immunoassays and automated immunoanalyser technologies to provide diagnostic outcomes for patients. It offers IDS-iSYS multi-discipline automated systems, which is based on chemiluminescence and absorbency technology is used for immunoassay testing. The company provides its products and services for diagnosis of bone metabolism, calcium metabolism, hypertension, chronic kidney disease mineral bone disorder, growth, fertility, autoimmunity, infectious disease, sarcoidosis, and allergy. Immunodiagnostic Systems Holdings PLC was founded in 1977 and is headquartered in Boldon, the United Kingdom.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
Ever wondered how to buy shares in Van Elle Holdings? We explain how and compare a range of providers that can give you access to many brands, including Van Elle Holdings.
Ever wondered how to buy shares in ULS Technology? We explain how and compare a range of providers that can give you access to many brands, including ULS Technology.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.